Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023
Portfolio Pulse from Benzinga Newsdesk
Genmab announced data from its phase 1/2 EPCORE™ NHL-2 trial, showcasing a 98% overall response rate and 87% complete metabolic response in patients with relapsed or refractory follicular lymphoma. The trial investigates epcoritamab in combination with rituximab-lenalidomide. Epcoritamab is co-developed by Genmab and AbbVie as part of their oncology collaboration.
June 09, 2023 | 7:26 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie is co-developing epcoritamab with Genmab, and the positive data from the EPCORE™ NHL-2 trial could strengthen AbbVie's oncology portfolio and boost its stock price.
The promising results from the EPCORE™ NHL-2 trial indicate that epcoritamab could become a significant treatment option for patients with relapsed or refractory follicular lymphoma. This could lead to increased revenue for AbbVie and strengthen its oncology portfolio, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Genmab's EPCORE™ NHL-2 trial data shows promising results for epcoritamab, a drug co-developed with AbbVie, potentially boosting the company's oncology portfolio.
The positive data from the EPCORE™ NHL-2 trial indicates that epcoritamab has the potential to become a significant treatment option for patients with relapsed or refractory follicular lymphoma. This could lead to increased revenue for Genmab and strengthen its oncology portfolio, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100